Orexin antagonists — DORAs, dual orexin receptor antagonists — are the newest mechanism in the sleep pharmacology toolkit. Suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq) block orexin-1 and orexin-2 receptors. Orexin is the wake-promoting neurotransmitter produced by the lateral hypothalamus; blocking it removes the brain's wake signal and permits sleep.
- Class
- Dual orexin receptor antagonists (DORAs)
- Mechanism
- Block both orexin-1 and orexin-2 receptors → reduces wakefulness signaling from lateral hypothalamus → permits sleep
- Typical dose
- Suvorexant 10-20 mg HS; lemborexant 5-10 mg HS; daridorexant 25-50 mg HS
- Half-life
- Suvorexant ~12h; lemborexant ~17-19h; daridorexant ~8h
- FDA indications
- Insomnia (sleep onset and maintenance)
- Key adverse effects
- Somnolence, fatigue, headache, abnormal dreams, sleep paralysis, cataplexy-like symptoms (rare), suicidal ideation (rare)
- Representative agents
- Suvorexant (Belsomra), lemborexant (Dayvigo), daridorexant (Quviviq)
Newest sleep mechanism (suvorexant 2014, lemborexant 2019, daridorexant 2022). Effect on both onset and maintenance (vs. melatonin agonists onset-only). Lower abuse liability than GABA modulators. Cost is the constraint. Daridorexant has shortest half-life, potentially least morning sedation.
The conceptual shift matters. Z-drugs and benzodiazepines enhance GABA-mediated inhibition globally — they suppress activity broadly, which produces sleep but also produces cognitive effects, motor effects, and risks of complex sleep behaviors. Orexin antagonists block one specific wake-promoting signal — sleep emerges by reducing arousal rather than amplifying inhibition. The pharmacology is more targeted.
Orexin antagonists (DORAs) are the newest hypnotic class — instead of broadly depressing the CNS, they block a specific wake-promoting signal.
Mechanism note: DORAs turn off the wake signal rather than depressing the whole CNS — giving a markedly better safety profile in older adults, the main reason they are displacing benzodiazepines and Z-drugs.
Clinically, DORAs work for both sleep onset and sleep maintenance — distinguishing them from melatonin agonists, which only work for onset. Effect sizes are modest but real. The next-morning impairment is less than with z-drugs at comparable subjective sleep effect.
Lower abuse liability than GABA modulators. Less withdrawal. Less complex sleep behavior risk. The dependence profile is more favorable.
Distinctive side effects reflect orexin's role in REM regulation. Vivid dreams. Sleep paralysis. Rare cataplexy-like phenomena — narcolepsy is the pathology of orexin loss, and pharmacologic orexin blockade transiently produces narcolepsy-like phenomena. Usually mild; occasionally limiting.
The constraint is cost. DORAs are brand-only and expensive. Insurance coverage is improving but inconsistent. For the patient who has tried z-drugs and is concerned about long-term use, or who has substance use history, or who needs sleep maintenance and not just onset, DORAs are a reasonable choice when access permits.
- Cost
- Suvorexant (Belsomra) ~$400/month. Lemborexant (Dayvigo) ~$400/month. Daridorexant (Quviviq) ~$500/month.
- Generic status
- All brand-only.
- Formulary typical
- Specialty tier with PA. Coverage improving but inconsistent.
- Access friction
- PA often requires documented failure of z-drug or BZD. Manufacturer co-pay programs for commercial patients.
Prescriber tip: For patients with substance use history or who need sleep maintenance (not just onset), orexin antagonists are clinically reasonable but the cost barrier is real. Document PA rationale specifically.
Together with CBT-I, melatonin agonists, and selective use of older sedative-hypnotics, DORAs round out a sleep treatment toolkit that's substantially better than what existed a decade ago.